Li, MM (Li, Manman)[ 1 ] ; Sun, YS (Sun, Yusheng)[ 1 ] ; Ma, CJ (Ma, Chenjun)[ 1 ] ; Hua, YY (Hua, Yingying)[ 1 ] ; Zhang, LF (Zhang, Liefeng)[ 1 ] *; Shen, J (Shen, Jian)[ 2 ]*(沈健)
[ 1 ] Nanjing Normal Univ, Sch Food Sci & Pharmaceut Engn, Nanjing 210046, Peoples R China
[ 2 ] Nanjing Normal Univ, Coll Chem & Mat Sci, Jiangsu Collaborat Innovat Ctr Biomed Funct Mat, Jiangsu Key Lab Biomed Mat, Nanjing 210046, Peoples R China
JOURNAL OF PHARMACEUTICAL SCIENCES 2021,110,268-279
The aim of the study is to design octaarginine (R8)-modified insulin-alginate nanoparticles (INS-SA/R8 NPs) as the oral insulin delivery system, and further investigate its penetrating mechanism. The characterization results indicated that the surface of INS-SA/R8 NPs was smooth and the average diameter was about 300 nm. INS-SA/R8 NPs exhibited a stronger stability in the simulated gastrointestinal fluids and had a better controlled release than unmodified alginate nanoparticles (INS-SA NPs). Moreover, INSSA/R8 NPs group had the strongest insulin transport capacity and the largest amount of insulin uptake in all experimental groups. Most importantly, the improvement of insulin intestinal uptake was further confirmed in rat intestine in vivo, and its penetrating mechanism might be involved in the production of endogenous nitric oxide (NO) signal molecule. In addition, in vivo hypoglycemic studies showed that orally administrated INS-SA/R8 NPs produced a better hypoglycemic effect as compared with INS-SA NPs in diabetic rats. Meanwhile, from the cytotoxicity analysis, INS-SA/R8 NPs were safe for oral administration. Taken together, INS-SA/R8 NPs was a good oral insulin delivery system, which might also be suitable for other protein drugs. (C) 2020 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
版权与免责声明:本网页的内容由收集互联网上公开发布的信息整理获得。目的在于传递信息及分享,并不意味着赞同其观点或证实其真实性,也不构成其他建议。仅提供交流平台,不为其版权负责。如涉及侵权,请联系我们及时修改或删除。邮箱:sales@allpeptide.com